Beyond the suppression of immune inhibitory signals by immune checkpoint inhibition via PD-1/PD-L1 or CTLA4, the use of cancer vaccines that induce the generation of high-quality tumor-specific T cells is a promising tool to mount immune responses against tumor specific target antigens, a field of intense investigation (2). Here, CTLA4 is linked to neoplasm.